巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Adaptimmune Therapeutics plc

ADAP
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Adaptimmune Therapeutics plc - 延遲價格・最後更新於 24/01 12:15
最高位
2.940
最低位
2.680
開市價
--
前收市價
2.885
成交量(千)
69.28
成交額(百萬)
1.23
買入
--
賣出
--
每手股數
--
市值(百萬)
457.68
市盈率
--
息率
--
差價
--
52週高低
7.340 - 2.680
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Adaptimmune Therapeutics plc
證券代碼
ADAP.US
所屬板塊
Biotechnology
公司業務
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.
發行量
155480701
公司總部
60 Jubilee Avenue, Milton Park
公司網址
http://www.adaptimmune.com
公司電郵
IR@adaptimmune.com
公司電話
+44 1235430000
暫無內容

關於

Adaptimmune Therapeutics plc(ADAP.US)所屬的行業板塊為Biotechnology。
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.
詳細公司背景可參考: http://www.adaptimmune.com